Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5816230 | Neuropharmacology | 2008 | 7 Pages |
Abstract
Endocannabinoids, including anandamide (arachidonoyl ethanolamide) have been implicated in the regulation of a growing number of physiological and pathological processes. Anandamide can be generated from its membrane phospholipid precursor N-arachidonoyl phosphatidylethanolamine (NAPE) through hydrolysis by a phospholipase D (NAPE-PLD). Recent evidence indicates, however, the existence of two additional, parallel pathways. One involves the sequential deacylation of NAPE by α,β-hydrolase 4 (Abhd4) and the subsequent cleavage of glycerophosphate to yield anandamide, and the other one proceeds through phospholipase C-mediated hydrolysis of NAPE to yield phosphoanandamide, which is then dephosphorylated by phosphatases, including the tyrosine phosphatase PTPN22 and the inositol 5â² phosphatase SHIP1. Conversion of synthetic NAPE to AEA by brain homogenates from wild-type and NAPE-PLDâ/â mice can proceed through both the PLC/phosphatase and Abdh4 pathways, with the former being dominant at shorter (<10 min) and the latter at longer (60 min) incubations. In macrophages, the endotoxin-induced synthesis of anandamide proceeds uniquely through the phospholipase C/phosphatase pathway.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Jie Liu, Lei Wang, Judith Harvey-White, Bill X. Huang, Hee-Yong Kim, Serge Luquet, Richard D. Palmiter, Gerald Krystal, Ravi Rai, Anu Mahadevan, Raj K. Razdan, George Kunos,